IO Biotech, Inc. announced a restructuring plan on September 25, 2025, which includes reducing its workforce by approximately 50% and incurring one-time charges of $1.0 to $1.5 million. The company aims to focus on advancing the development of Cylembio, amid regulatory insights following an FDA meeting.